title: Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.
abstract: OBJECTIVE
  To assess the efficacy and safety of an intravitreal injection of bevacizumab (Avastin(R)) for myopic choroidal neovascularisation (mCNV).
  
  
  METHODS
  Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months.
  
  
  RESULTS
  The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed.
  
  
  CONCLUSIONS
  Intravitreal injection of bevacizumab seems to be an effective and safe treatment for mCNV.
authors.affiliation: Department of Ophthalmology, Osaka University Medical School, 2-2 Yamadaoka, E7, Suita, Osaka 565-0871, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sakaguchi
authors.forename: Y
authors.initials: Y
authors.lastname: Ikuno
authors.forename: F
authors.initials: F
authors.lastname: Gomi
authors.forename: M
authors.initials: M
authors.lastname: Kamei
authors.forename: M
authors.initials: M
authors.lastname: Sawa
authors.forename: M
authors.initials: M
authors.lastname: Tsujikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Oshima
authors.forename: S
authors.initials: S
authors.lastname: Kusaka
authors.forename: Y
authors.initials: Y
authors.lastname: Tano
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D005584:Fovea Centralis / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab